A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors

Victor M. Santana, William C. Zamboni, Mark N. Kirstein, Ming Tan, Tiebin Liu, Amar Gajjar, Peter J. Houghton, Clinton F. Stewart

Research output: Contribution to journalArticlepeer-review

60 Scopus citations

Abstract

Purpose: To assess the use of a pharmacokinetically guided topotecan strategy and evaluate the toxicity of protracted i.v. topotecan in children with recurrent solid tumors. Experimental design: Fifteen children with measurable relapsed or refractory solid tumors received topotecan i.v. over 30 min 5 days a week for two consecutive weeks. Doses were individualized based on the patient's topotecan systemic clearance to attain a single day topotecan lactone area under the plasma concentration time curve (AUC) of 120-180 ng/ml × h (cohort 1) or 80-120 ng/ml × h (cohort 2). Clinical responses and toxicity were assessed by standard criteria. Results: Twenty-nine courses of topotecan were administered, 11 in cohort 1 and 18 in cohort 2. The median topotecan dosages required to achieve the target AUCs for cohorts 1 and 2 were 4 mg/m2 (range, 2.6-6) and 3 mg/m2 (range, 2.6-4.2), respectively. The intersubject variance for topotecan clearance exceeded the intrasubject variance by 2-fold. With the pharmacokinetic targeting approach, we observed that 78% (46 of 59) of the measured AUC values were within the target range. The median number of days to an absolute neutrophil count ≥500/mm3 was similar between the two cohorts; however, febrile neutropenia and serious infections limited our ability to deliver drug dosages needed to secure the higher systemic exposure (cohort 1). Five partial responses were observed. Conclusion: Protracted topotecan dosing using a pharmacokinetic strategy was possible in this heavily pretreated group of children.

Original languageEnglish (US)
Pages (from-to)633-640
Number of pages8
JournalClinical Cancer Research
Volume9
Issue number2
StatePublished - Feb 1 2003

Fingerprint Dive into the research topics of 'A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors'. Together they form a unique fingerprint.

Cite this